Antiseptic Mouth Rinses to Reduce Salivary Viral Load in COVID-19 Patients (BUCOSARS)
Covid19
About this trial
This is an interventional prevention trial for Covid19 focused on measuring COVID-19, MOUTHWASHES, SALIVA, VIRAL LOAD, ORAL, CLINICAL TRIAL
Eligibility Criteria
Inclusion Criteria:
- Lower than 7 days from the positive SARS-COV-2 PCR test of a nasopharyngeal sample
- Have the ability to donate saliva samples and perform mouthwash
Exclusion Criteria:
- Patient participation in a COVID-19 research study using experimental drugs,
- Use of an antiseptic mouthwash for 48 h before the start of the study
- Any known hypersensitivity or allergy to components of the mouthwashes.
Sites / Locations
- Alejandro Mira
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Experimental
Experimental
Experimental
Experimental
Placebo Comparator
Povidone-iodine 2% (Betadine© bucal 100 mg/ml)
Hydrogen peroxide 1% (Oximen® 3%)
Clorhexidine 0,12% (Clorhexidine Dental PHB©)
Cetylpyridinium chloride 0,07% (Vitis Xtra Forte©)
Control (Distilled Water)
Povidone-iodine 2% (Betadine© bucal 100 mg/ml) (Mylan Pharmaceuticals, S.L., Spain). The concentration was adjusted to those previously indicated by diluting commercial formulas with distilled water minutes before rinsing (3 mL of povidone-iodine 10% for oral use - Betadine© with 12 mL of distilled water).
Hydrogen peroxide 1% (Oximen® 3%) (Reig Jofré, S.A., Spain). The concentration was adjusted to those previously indicated by diluting commercial formulas with distilled water minutes before rinsing (5 mL of hydrogen peroxide 3% - Oximen© with 10 mL of distilled water).
Clorhexidine 0,12% (Clorhexidine Dental PHB©) contains clorhexidine (C22H30N10Cl2). Rinses were ready to use in their commercial formulas.
Cetylpyridinium chloride 0,07% (Vitis Xtra Forte©) contains cetylpyridinium chloride (C21H38ClN). Rinses were ready to use in their commercial formulas.
Distilled water.